Neu­rol­o­gists val­ue speed and ef­fi­ca­cy over safe­ty for ALS pipeline drugs, study finds

Neu­rol­o­gists who were asked about new treat­ments for amy­otroph­ic lat­er­al scle­ro­sis (ALS) say they val­ue ef­fi­ca­cy and qual­i­ty-of-life im­prove­ments over safe­ty for drugs in de­vel­op­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.